Literature DB >> 21070569

Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.

Rufus Cartwright1, Sushma Srikrishna, Linda Cardozo, Dudley Robinson.   

Abstract

OBJECTIVE: • To assess the measurement characteristics of the Patient Perception of Intensity of Urgency Scale (PPIUS) in patients with overactive bladder (OAB). PATIENTS AND METHODS: • Adult women with at least a 3-month history of OAB. The design was a 4-week, double-blind, randomized, placebo-controlled trial of transdermal oxybutynin, with a 2-week placebo run-in and 8-week, open-label extension. • Symptom improvement was assessed using 3-day bladder diaries incorporating the PPIUS, and disease-specific health-related quality of life was assessed using the King's Health Questionnaire (KHQ). Convergent validity was shown by correlation with the KHQ, and other bladder diary variables. Known groups validity was assessed by comparison of baseline mean urge ratings, and urgency episode frequency for continent and incontinent patients, and by comparison with the same measures from a historical control group of 40 asymptomatic female volunteers. • Between- and within-groups responsiveness was assessed using standardized effect sizes (Cohen's d and effect size r). Reliability was assessed for the two arms of the trial at different time points and intervals, using intraclass correlation (ICC) and a t-test for the difference between mean scores.
RESULTS: • In total, 96 women were randomized. Urgency episode frequency showed moderate correlation with total KHQ score (r = 0.500, P < 0.001) and with daytime and night-time voiding frequency. • There were significant differences in continent and incontinent subgroups for mean urge ratings (difference in means, -0.61/void, P < 0.001), and urgency episodes (difference in means, -2.67 episodes/day, P < 0.001), as well as between OAB patients and normal controls (mean urge rating: difference in means 1.22 per void, P < 0.001; urgency episodes: difference in means 2.93 episodes/day, P < 0.001). • Between-groups analysis of effect size found that urgency episode frequency (d = 0.679, r = 0.321) was more responsive than mean urge rating (d = 0.480, r = 0.233). In both subgroups, urgency episode frequency (d = 0.421-0.454, r = 0.206-0.222) had better within-groups responsiveness than mean urge rating. • Urgency episodes (ICC, 0.65-0.81) were measured more reliably than urgency urinary incontinence episodes (ICC, 0.50-0.65).
CONCLUSIONS: • Assessment of urgency episodes using the PPIUS shows good reliability, excellent known groups validity, high responsiveness and convergence with subjective measures of severity. • PPIUS is freely available, and should be useful in both clinical practice and research studies when assessing women with urgency, with or without urgency urinary incontinence.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070569     DOI: 10.1111/j.1464-410X.2010.09684.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  18 in total

1.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

Review 2.  The placebo effect in overactive bladder syndrome.

Authors:  Altaf Mangera; Christopher R Chapple; Zoe S Kopp; Melanie Plested
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

Review 3.  Self-report measurement of lower urinary tract symptoms: a commentary on the literature since 2011.

Authors:  James W Griffith
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

Review 4.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

5.  Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder.

Authors:  G Vijaya; R Cartwright; A Derpapas; P Gallo; R Fernando; V Khullar
Journal:  Int Urogynecol J       Date:  2013-02-02       Impact factor: 2.894

6.  Prospective randomized comparison of the transobturator mid-urethral sling with the single-incision sling among women with stress urinary incontinence: 1-year follow-up study.

Authors:  Michaela Jurakova; Martin Huser; Ivan Belkov; Petr Janku; Robert Hudecek; Petr Stourac; Jiri Jarkovsky; Pavel Ventruba
Journal:  Int Urogynecol J       Date:  2015-12-02       Impact factor: 2.894

7.  Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder.

Authors:  Sherilyn M Notte; Thomas S Marshall; Misun Lee; Zalmai Hakimi; Isaac Odeyemi; Wen-Hung Chen; Dennis A Revicki
Journal:  BMC Urol       Date:  2012-09-07       Impact factor: 2.264

8.  Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Jameel Nazir; Lars Heemstra; Anke van Engen; Zalmai Hakimi; Cristina Ivanescu
Journal:  BMC Urol       Date:  2015-05-09       Impact factor: 2.264

9.  A phase II dose-ranging study of mirabegron in patients with overactive bladder.

Authors:  Christopher R Chapple; Vladimir Dvorak; Pjotr Radziszewski; Philip Van Kerrebroeck; Jean Jacques Wyndaele; Brigitte Bosman; Peter Boerrigter; Ted Drogendijk; Arwin Ridder; Ingrid Van Der Putten-Slob; Osamu Yamaguchi
Journal:  Int Urogynecol J       Date:  2013-03-08       Impact factor: 2.894

10.  Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Authors:  V W Nitti; V Khullar; P van Kerrebroeck; S Herschorn; J Cambronero; J C Angulo; M B Blauwet; C Dorrepaal; E Siddiqui; N E Martin
Journal:  Int J Clin Pract       Date:  2013-05-21       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.